Amid Obesity Bidding War, Amgen Believes It Can Stand Out in Crowded Space
Amgen remains confident in its obesity asset MariTide, for which it has launched a broad Phase III program.
Amid Obesity Bidding War, Amgen Believes It Can Stand Out in Crowded Space Read More »
